Issam S. Hamadeh

**-** ******** ****, *** **A,

Queens, NY, 11101

adxi2x@r.postjobfree.com

Education & Training

University of Florida Dec 2012-April 2016

Pharmacotherapy & Translational Research

Gainesville, FL

Fellowship in Pharmacogenetics/Precision Medicine

Teaching Certificate Program July 2013-June 2014

University of Florida

Gainesville, FL

Purdue University Apr 2009

School of Pharmacy and Pharmaceutical Sciences

West Lafayette, Indiana

Doctor of Pharmacy

Professional Experience

Multiple Myeloma clinical pharmacy specialist March 2022- present

Memorial Sloan Kettering Cancer Center, NY

Hematology clinical pharmacy specialist, Jan 2021-May 2021

Johns Hopkins, Baltimore, MD

Hematology/Oncology clinical pharmacist- May 2016-Dec 2020

pharmacogenetics specialist, Levine Cancer Institute,

Atrium Health, Charlotte, NC

Providing patient education and counseling

Developing and updating chemotherapy protocols and clinical pathways

Writing and verification of chemotherapy orders

Management of chemotherapy related complications and providing supportive care

Providing general and patient specific drug information to physicians and other health care providers

Precepting Pharm.D. students

Implementing/integrating precision medicine into the routine clinical care of hematology/oncology patients

Conducting pharmacogenetics research

Postdoctoral associate, University of Florida, Dec 2012-April 2016

Gainesville

Preceptor, Lebanese International University, Beirut May 2011-Sept 2012

Clinical Pharmacist, Tawam Hospital May 2009-April 2011

Al Ain, Abu Dhabi

Rounded with adult medicine, cardiology, and oncology/hematology teams to provide drug information and monitor patients’ responses to their medications

Reviewed patients’ medications regimens

Provided patient education in-house and upon discharge

Monitored antibiotic therapy and other medications that require additional laboratory monitoring

Certifications:

Board Certified Oncology Pharmacist (BCOP) 2011-present

Research Projects

Impact of a clinical pharmacist intervention on pain and Dec 2016-present

symptom management in ambulatory cancer patients.

The goal of this research is to determine whether frequent follow up assessments and pharmacist’s driven interventions improve pain and related symptoms among outpatient cancer patients.

Investigating the Impact of Gain of Function Variant Allele, Dec 2013-April 2016

CYP2C19*17 on Voriconazole Exposure in Patients with

Invasive Fungal Infections.

The primary objective of this study is to determine whether the CYP2C19 ultrarapid metabolizer phenotype is associated with voriconazole underexposure in patients treated with the standard weight-based regimen for invasive fungal infections (IFIs).

Research Grants

Current

Swim Across America Aug 2020-present

Investigating impact of polymorphisms in pharmacokinetic genes on tolerability of TKIs for treating CML and Ph+ALL.

Time period: August 2020-August 2022

Amount: $80,000

Role: Co-Prinicipal Investigator

Atrium Foundation Dec 2019-present

Identification of genetic markers associated with cardiovascular toxicity of ibrutinib in patients with CLL.

Time period: Dec 2019-April 2021

Amount: $120,000

Role: Co-Principal Investigator

Leukemia Research Foundation Jan 2019-present

Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms and NPM1 mutation status in AML.

Time period: January 2019-January 2021

Amount: $100,000

Role: Co-Investigator

Hospital Oncology Pharmacy Association (HOPA) Dec 2016-present

Impact of a clinical pharmacist intervention on pain and symptom management in ambulatory cancer patients.

Time period: December 2016-December 2017

Amount: $ 30,000

Role: Co-Investigator

Completed

NIH/NCATS Clinical and Translational Science Award to the University of Florida (UL1 TR000064)

Title: UF-CTSI Pilot Project Award

Time period: February 2015- February 2016

Amount: $ 10,928

Role: Principal investigator

Publications (Chronological order)

1. Hamadeh IS, Langaee TY, Johnson JA, et al. Impact of CYP2D6 Polymorphisms on the

Clinical Efficacy and Tolerability of Metoprolol Tartrate. Clinical Pharmacology and

Therapeutics. 2014 Aug; 96(2):175-81.

2. Langaee TY, Hamadeh IS, Johnson JA, et al. A Novel Simple Method for Determining

CYP2D6 Gene Copy Number and Identifying Alleles with Duplication/Multiplication. Plos

One. 2015 Jan 27; 10(1): e0113808.doi:10.1371/journal.pone.0113808

3. Langaee TY, Hamadeh IS. Applied Molecular and Cellular Biology. In Pharmacogenomics,

Applications to Patient Care, 3rd Edition.

4. Johnson AJ, Hamadeh IS, Langaee TY. Loss of heterozygosity at the CYP2D6 Locus in

Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies. Journal of National

Cancer Institute. 2015 Jan 31; 107(2). doi: 10.1093/jnci/dju437

5. Langaee T, Zhong G, Hamadeh I, Solayman M, McDonough C, Shroads A, Stacpoole P,

James M. The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression.

Pharmacogenetics and Genomics. 2015 May; 25(5):239-245.

6. Hamadeh IS, Bridget A. Ngwa, Yan Gong. Drug Induced Osteonecrosis of the Jaw.

Cancer Treatment Reviews. 2015 May; 41(5):455-464.

7. Xiaoyan Zhang, Issam S. Hamadeh, Shuang Song, Lawrence J. Lesko, Yan Gong.

Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse

Event Reporting System (FAERS). Journal of Bone and Mineral Research. 2015 Aug 19.

doi: 10.1002/jbmr.2693.

8. Issam Hamadeh, Mohamed Shahin, Sarah M. Lima, Felipe Oliveira, Latrice Wilson,

Sherief Khalifa, Taimour Y. Langaee, Larisa H. Cavallari, Julie A. Johnson. Impact of

GGCX, STX1 and FPGS Polymorphisms on Warfarin Dose Requirements in Caucasians and

Egyptians. Clinical and Translational Science. 2016; 9(1): 36-42.

9. Issam IS, Bourdage KL, Davis AS, Moreb JS. Pomalidomide Induced Hypothyroidism in

a Multiple Myeloma Patient: A Case Report. Annals of Hematology and Oncology.

2015; 2(8):1057-1060

10. Yan Gong, Issam Hamadeh, Joseph Katz, Alberto Riva, Peter Lakatos, Gian Andrea

Pelliccioni, Jan Moreb, Taimour Y. Langaee. Whole Exome Sequencing Analysis of

Bisphosphonate-Associated Osteonecrosis of the Jaw in Multiple Myeloma Patients (Under

Review).

11. Lindsay McCullough, Amy C. Davis, Issam Hamadeh, Ashley Richards, Jan Moreb.

Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be

the Last Word: Two Cases Illustrated. International Journal of Medical and

Pharmaceutical Case Reports. 2016; 7(3): 1-7.

12. Owusu Obeng A, Hamadeh I, Smith M. Review of Opioid Pharmacogenetics and

Considerations for Pain Management. Pharmacotherapy. 2017 Sep;37(9):1105-112.

13. Hamadeh IS, Klinker KP, Borgert SJ, et al. Impact of the CYP2C19 genotype on

voriconazole exposure in adults with invasive fungal infections. Pharmacogenetics

and Genomics.2017 May;27(5):190-196.

14. Yang G, Hamadeh IS, Katz J, Riva A, Lakatos P, Balla B, Kosa J, Vaszilko M, Davis N,

Langaee TY, Moreb JS, Gong Y. SIRT1/HERC4 locus associated with bisphosphonate-

induced osteonecrosis of the jaw: An Exome-Wide Association Analysis. Journal of Bone

and Mineral Research. 2017 Aug 30. doi: 10.1002/jbmr.3285.

15. Issam S Hamadeh, Jai N. Patel, Stephanie Rusin, et al. Personalizing aromatase

inhibitor therapy in patients with breast cancer. Cancer Treatment Reviews. 2018.

70:47-55.

16. Issam S Hamadeh, Qing Zhang, Nury Steuerwald, et al. Effect of CYP3A4,

CYP3A5, and ABCB1Polymorphisms on Intravenous Tacrolimus Exposure and Adverse

Events in Adult Allogeneic Stem Cell Transplant Patients. Biol Blood Marrow Transplant.

2019; 25:656-663.

17. M Junaid Hussain, Myra M Robinson, Issam Hamadeh, et al. Daratumumab,

pomalidomide and dexamethasone combination therapy in daratumumab and/or

pomalidomide refractory multiple myeloma. Br J Haematol. 2019;186(1):140-144.

18. Jai N. Patel, Issam S Hamadeh, Myra Robinson, et al. Evaluation of CYP2C19

Genotype Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell

Transplant. Clin Pharmacol Ther. 2020 Mar;107(3):571-579.

19. Issam S Hamadeh, Emily S Reese, Justin R Arnall et al. Safety and Cost Benefits of

Rapid Daratumumab Infusion Protocol. Clinical Lymphoma Myeloma and Leukemia.

2020;20(8): 526-532.

20. Issam Hamadeh, Shebli Atrash, Ashley Matusz Fisher, et al. Advances and Future

Prospects in Newly Diagnosed Multiple Myeloma Patients. Gene Therapy. 2020 June.

doi.org/10.1002/acg2.96

21. Shebli Atrash, Issam S Hamadeh, Ashley Matusz Fisher et al. Approaching the First

Relapse after Autologous Transplant in Multiple Myeloma. Advances in Cell and Gene

Therapy. 2020 June. doi.10.1002/acg2.95

22. Barry Paul, Issam S. Hamadeh, Shebli Atrash et al Daratumumab Subcutaneous

Formulation for the Treatment of Multiple Myeloma. Expert Opinion on Biological

Therapy. 2020 August. doi:10.1080/14712598.2020.1806231.

23. Ragon BK, Hamadeh IS, Vestal G, et al. Response to hypomethylating agents based on

cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in

acute myeloid leukemia. AACR Annual Meeting 2020. doi:10.1158/1538-7445. AM2020-

1920.

24. Issam S Hamadeh, Zainab Shahid, Manisha Bhutani, et al. Genetic polymorphisms

associated with clostridium difficile infection in multiple myeloma patients undergoing

autologous stem cell transplantation. Journal of Clinical Oncology 38(15_suppl):8522-

8522.

25. Mato AR, Ghosh N, Schuster SJ…Issam S Hamadeh… Phase 2 Study of the Safety and

Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor

Therapy. Blood 2020. doi:10.1182/blood.202*******.

26. Ekaterina Kachur, Danya Roshdy, Issam Hamadeh et al. Single Center Experience with

Use of Letermovir for Treatment of CMV Infection in Stem Cell Transplant Recipients.

Transplant Infectious Diseases 2020. doi:10.1111/tid.13502.

27. Issam S Hamadeh, Michael R Grunwald, Allison Martin et al. Impact of Letermovir

Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant

Recipients. Transplantation and Cellular Therapy 2021. 27(3_suppl): S124.

28. Issam S Hamadeh, Donald C Moore, Allison Martin et al. Transition from Intravenous to

Subcutaneous Daratumumab Formulation in Clinical Practice. Clinical Lymphoma

Myeloma and Leukemia. 2021 Jul;21(7):470-475.

29. Barry Paul, Shebli Atrash, Manisha Bhutani, Peter Voorhees, Issam S Hamadeh, Saad

Z Usmani. An evaluation of subcutaneous daratumumab for the treatment of multiple

Myeloma. Expert Rev Hematol. 2020 Aug;13(8):795-802.

30. Issam Hamadeh, Ryan Jacobs, Bei Hu et al. Identification of genetic markers

associated with ibrutinib-related cardiovascular toxicity. Journal of Clinical Oncology

May 2021. 39 (15-suppl): 7526-7526.

Teaching Experience

Lecturer, Pharmacotherapy II (PHA 5782) Jan 2013-April 2016

University of Florida, College of Pharmacy

Acute Coronary Syndromes (ACS), ACS cases

Lecturer, Clinical Applications Pharmacogenomics (PHA 5933) Sept 2014-April 2016

University of Florida, College of Pharmacy

CYP2D6 Genetics and Clinical Implications

Pharmacogenomics of HIV and Antifungal Medications

Presentations

1. CE presentation of research: CYP2C19 polymorphisms and voriconazole exposure

in patients with invasive fungal infections. Presented at University of Florida,

Pharmacotherapy and Translational Research Seminars, FL, April 2015.

2. CE presentation of research: Impact of CYP2D6 polymorphisms on metoprolol response.

Presented at University of Florida, Pharmacotherapy and Translational Research Seminars,

FL, Nov 2013

3. Metabolic Syndrome. Presented to faculty and PharmD candidates, Methodist Hospital,

IN, Jan 2009

4. Erlotinib plus Paclitaxel in Her-2 Negative Breast Cancer Patients. Presented to faculty

and PharmD candidates, Indiana University Hospital, IN, Feb 2009

5. Dosage Adjustment of Antimicrobials in Patients Undergoing Continuous Renal

Replacement Therapy. Presented to faculty, First Data Bank, Indianapolis, IN, Nov 2008

6. Etanercept and Risk of Cytomegalovirus Pneumonitis. Presented to faculty and PharmD

candidates, Wishard Health Services, Indianapolis, IN, Oct 2008

7. Metformin and Sitagliptin Combination: Is It Synergistic? Presented to faculty and

PharmD candidates, Wishard Health Services, Indianapolis, IN, Sept 2008

8. Acute and Chronic Complications of Diabetes Mellitus. Presented to faculty and

PharmD candidates, Wishard Health Services, Indianapolis, IN, Sept 2008

9. Complications of Hypertension. Presented to faculty and PharmD candidates, Wishard

Health Services, Indianapolis, IN, Sept 2008

10. ACEIs and ARBs in Diabetic Nephropathy. Presented to faculty and PharmD candidates,

Wishard Health Services, Indianapolis, IN, Aug 2008

11. Role of Nesiritide in Decompensated Heart Failure. Presented to faculty and PharmD

Candidates, Wishard Health Services, Indianapolis, IN, Aug 2008

12. Dronedarone Increases risk of Mortality in Patients with Chronic Heart Failure.

Presented to faculty and PharmD candidates, Wishard Health Services, Indianapolis, IN,

July 2008

Advanced Experiential Learning:

Ambulatory Care Feb-March 2009

Methodist Medical Group #500

Indianapolis, Indiana

Preceptor: Nahid Jamzadeh, RPh

Oncology Jan-Feb 2009

University Hospital-Clarian Health

Indianapolis, Indiana

Preceptor: Kellie Jones, PharmD, BCOP

Drug Information Oct-Nov 2008

First Data Bank #500

Indianapolis, Indiana

Preceptor: Dennis Hays, PharmD

Infectious Diseases Sept-Oct 2008

Wishard Memorial Hospital

Indianapolis, Indiana

Preceptor: Sharon Erdman, PharmD

Ambulatory Care Aug-Sept 2008

North Arlington Clinic #2505

Indianapolis, Indiana

Preceptor: Jasmine Gonzalvo, PharmD, BCPS

Adult Medicine July-Aug 2008

Wishard Memorial Hospital

Indianapolis, Indiana

Preceptor: Kevin Sowinski, PharmD, BCPS

Long Term Care June-July 2008

Grandview Pharmacy #675

Brownsburg, Indiana

Preceptor: Glenn Eldrige, RPh

Memberships

American College of Clinical Pharmacists (ACCP), member 2009-present

American Society of Clinical Pharmacology & Therapeutics (ASCPT), member 2013-present

Hematology/Oncology Pharmacy Association (HOPA), member 2016-present

American Society of Hematology (ASH), member 2019-present

American Society of Clinical Oncology (ASCO), member 2019-present

Scientific Reviewer:

PLosOne 2013-present

Pharmacovigilance 2013-present

Clinical Therapeutics 2013-present

Journal of Clinical Pharmacology 2015-present

Genetic Testing and Molecular Markers 2015-present

Awards and Honors

Key Engagement Award, Carolinas HealthCare System, Division of 2017

Pharmacy Services. Genotype Guided dosing of Voriconazole for Prophylaxis in hematopoietic stem cell transplant patients.

Annual Research Showcase Poster Competition, College of Pharmacy, 2014

University of Florida, Post-doctoral Fellowship Division.

Dean's List/Semester Honors 2006-2008

Contact this candidate